产品说明书

BLU-945

Print
Chemical Structure| 2660250-10-0 同义名 : ZL-2313
CAS号 : 2660250-10-0
货号 : A1547532
分子式 : C28H37FN6O3S
纯度 : 95%
分子量 : 556.695
MDL号 : N/A
存储条件：

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(188.61 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • EGFR/ErbB1
描述 BLU-945 is a potent, highly selective, reversible, and orally active inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It is effective against EGFR mutations including L858R, exon 19 deletions, T790M, and C797S mutations. BLU-945 is used in lung cancer research, including studies on non-small cell lung cancer (NSCLC)[1][2][3].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.80mL

0.36mL

0.18mL

8.98mL

1.80mL

0.90mL

17.96mL

3.59mL

1.80mL
参考文献

[1]John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1.

[2]Sun Min Lim, et al. BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitor with intracranial activity, demonstrates robust in vivo anti-tumor activity in models of osimertinib-resistant non-small cell lung cancer.

[3]Meredith S Eno, et al. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. J Med Chem. 2022 Jul 28;65(14):9662-9677.